Radiotherapy and platinum-based chemotherapy in head and neck squamous cell carcinoma create persistent senescent cells that fundamentally alter the extracellular matrix through their senescence-associated secretory phenotype (SASP). These therapy-induced senescent cells modify collagen density, alignment, and crosslinking patterns, which directly impacts tumor invasion pathways, immune cell access, blood vessel perfusion, and post-treatment fibrosis severity. This finding illuminates a critical but underappreciated consequence of standard cancer treatments: while initially beneficial for tumor control, the persistent senescent cells become problematic architects of tissue dysfunction. The research connects therapy-induced senescence to oral submucous fibrosis, a precancerous condition characterized by progressive tissue stiffening. This mechanistic understanding opens therapeutic possibilities beyond traditional cancer treatment. Senolytic drugs that eliminate senescent cells, senomorphic compounds that suppress their harmful secretions, or matrix-normalizing therapies could potentially improve treatment outcomes and reduce long-term complications. However, the challenge lies in distinguishing therapy-induced senescence from age-related inflammaging and chronic tissue injury in these patients. The proposed integration of spatial pathology with quantitative collagen imaging represents a sophisticated approach to mapping these complex tissue changes, potentially enabling precision interventions that address both cancer control and quality of life preservation.